Description

3-(4-Bromophenyl)-2-Methyl-4-Oxo-Quinazoline-7-Carboxylic Acid is a high-purity, advanced pharmaceutical intermediate with a distinct quinazoline core structure. This compound is valued for its role as a critical building block in the synthesis of complex active pharmaceutical ingredients (APIs), particularly those targeting specific therapeutic pathways. It is essential for research and development chemists and manufacturers in the pharmaceutical and fine chemical industries who require reliable, high-quality intermediates for drug discovery and process development.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of novel quinazoline-based drug candidates, particularly in oncology and kinase inhibitor research.
• Chemical Synthesis Building Block: Used in organic synthesis for constructing complex heterocyclic frameworks due to its reactive carboxylic acid and bromophenyl functional groups.
• Research & Development: Serves as a standard or reference compound in medicinal chemistry labs for structure-activity relationship (SAR) studies.
• API Manufacturing: Employed in the scaled-up production of target active pharmaceutical ingredients under controlled GMP-like conditions.
• Biochemical Research: Potential use as a tool compound for probing biological mechanisms in academic and industrial research settings.

Basic Information

Product Name	3-(4-Bromophenyl)-2-Methyl-4-Oxo-Quinazoline-7-Carboxylic Acid
CAS No.	74101-57-8
Molecular Formula	C16H11BrN2O3
Molecular Weight	359.18 g/mol
Synonyms	7-Carboxy-3-(4-bromophenyl)-2-methyl-4(3H)-quinazolinone; 3-(p-Bromophenyl)-2-methyl-4-oxo-3,4-dihydroquinazoline-7-carboxylic Acid; 2-Methyl-3-(4-bromophenyl)-4-oxo-3,4-dihydroquinazoline-7-carboxylic Acid; 74101-57-8; Quinazoline-7-carboxylic acid, 3-(4-bromophenyl)-2-methyl-4-oxo-; 3-(4-Bromophenyl)-2-methyl-4-oxo-3,4-dihydroquinazoline-7-carboxylic acid
EINECS	Contact for details

Quality Control

Our 3-(4-Bromophenyl)-2-Methyl-4-Oxo-Quinazoline-7-Carboxylic Acid is manufactured under strict quality management systems. Every batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation via spectroscopic methods, to ensure it meets the high standards required for pharmaceutical R&D and production. A comprehensive Certificate of Analysis (COA) detailing purity, impurities, and physical characteristics is provided with each shipment to guarantee traceability and consistency.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). The product should be kept under inert conditions if long-term storage is required. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.